The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

It's the longest-lasting wearable on the market. The G7 15-day sensor builds on the technology and performance of the Dexcom G7 CGM, which has proven to lower A1C and reduce hyper- and hypoglycemia.

Credit: Dexcom. The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

We anticipate Dexcom can continue to offer new features, such as lengthening sensor life, shrinking the size and profile of the CGM, making the insertion less painful, and improving accuracy.

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, we’re proud to offer the longest lasting wearable and most accurate CGM, giving people ...

Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...